Shire Human Genetic Therapies, Inc.
Overview
Shire Human Genetic Therapies, Inc. specializes in the development and commercialization of therapies for rare genetic disorders. It operates as a subsidiary of Takeda Pharmaceutical Company Limited, enhancing Takeda's focus on rare diseases through innovative treatments.
Therapeutic areas
FDA compliance signals
8 FDA enforcement records linked to this company.
- recall — Class I2019-10-02
Defective Delivery System: potential risk of rubber stopper particles clogging the needle and leading to underdosing
- recall — Class I2019-10-02
Defective Delivery System: potential risk of rubber stopper particles clogging the needle and leading to underdosing
- recall — Class I2019-10-02
Defective Delivery System: potential risk of rubber stopper particles clogging the needle and leading to underdosing
- recall — Class I2019-10-02
Defective Delivery System: potential risk of rubber stopper particles clogging the needle and leading to underdosing
- 4832015-07-15
Procedures not in writing, fully followed
- 4832015-07-15
Training--operations, GMPs, written procedures
- 4832014-08-06
Late submission of 15-day report
- recall — Class I2014-04-30
Presence of Particulate Matter; Particulates identified as stainless steel and barium sulfate.
Is this Shire Human Genetic Therapies, Inc.? Get in front of buyers actively sourcing.
We route real sourcing requests from pharma buyers to vetted, verified partners — qualified leads, not just a listing. Tell us what you make and we'll be in touch about becoming a Verified Supplier Partner.
Related companies
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 7 days.